India has denied an appeal by Roche on a patent claim for eye infection treatment Valcyte for AIDS patients, the Economic Times reports.
Social media success in consumer marketing has advanced beyond counting fans and followers. Today it's all about shares, retweets and links that indicate real consumer engagement with brands....
Merck's Keytruda and Bristol-Myers' Opdivo may have the next-gen cancer immunotherapy market to themselves for now. But Roche is in catch-up mode, and some new data add to its case for a sooner-rather-than-later regulatory approval.
China's FDA has approved Roche's Avastin (bevacizumab) for an additional indication of non-small lung cancer, a pending decision that was tipped in the first quarter earnings call.
Armed with positive results from two studies, Roche is one step closer to entering the MS market. And when it does, other players in the field had better watch out, analysts say: Formulary pressure will be ramping up.
Multinational drug firms in Australia faced a string of barbs in hearings held by a Senate panel into transfer pricing that included a reference to a fictitious German World War II prison camp guard.
Flat news is good news. Pharma spending on advertising and promotional expenses will dip by just 1.7% next year, according to Schonfeld & Associates' annual Advertising Ratios & Budgets. That means a total of more than $21 billion in ad spending and just a bit healthier than last year's decline of 2%.
Roche's Ventana Medical Systems has just received FDA approval of its Ventana ALK (DF53) as a companion diagnostic for Pfizer's Xalkori to treat non-small cell lung cancer.
Sequenom suffered a stinging defeat in its patent battle against Roche's Ariosa Diagnostics unit, as a U.S. appeals court ruled that the company's patent for its noninvasive prenatal test was invalid.
Roche's Ariosa Diagnostics nabbed a CE mark for software for its noninvasive prenatal test, a win for the company months after it scored expanded coverage for the tool in the U.S.